JP2023515821A5 - - Google Patents

Info

Publication number
JP2023515821A5
JP2023515821A5 JP2022551247A JP2022551247A JP2023515821A5 JP 2023515821 A5 JP2023515821 A5 JP 2023515821A5 JP 2022551247 A JP2022551247 A JP 2022551247A JP 2022551247 A JP2022551247 A JP 2022551247A JP 2023515821 A5 JP2023515821 A5 JP 2023515821A5
Authority
JP
Japan
Application number
JP2022551247A
Other languages
Japanese (ja)
Other versions
JPWO2021171257A5 (https=
JP7748377B2 (ja
JP2023515821A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/051636 external-priority patent/WO2021171257A1/en
Publication of JP2023515821A publication Critical patent/JP2023515821A/ja
Publication of JP2023515821A5 publication Critical patent/JP2023515821A5/ja
Publication of JPWO2021171257A5 publication Critical patent/JPWO2021171257A5/ja
Application granted granted Critical
Publication of JP7748377B2 publication Critical patent/JP7748377B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022551247A 2020-02-28 2021-02-26 抗axl抗体及び組成物 Active JP7748377B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062982852P 2020-02-28 2020-02-28
US62/982,852 2020-02-28
PCT/IB2021/051636 WO2021171257A1 (en) 2020-02-28 2021-02-26 Anti-axl antibodies and compositions

Publications (4)

Publication Number Publication Date
JP2023515821A JP2023515821A (ja) 2023-04-14
JP2023515821A5 true JP2023515821A5 (https=) 2024-03-01
JPWO2021171257A5 JPWO2021171257A5 (https=) 2024-03-01
JP7748377B2 JP7748377B2 (ja) 2025-10-02

Family

ID=75426640

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022551247A Active JP7748377B2 (ja) 2020-02-28 2021-02-26 抗axl抗体及び組成物

Country Status (17)

Country Link
US (1) US11807688B2 (https=)
EP (1) EP4110824A1 (https=)
JP (1) JP7748377B2 (https=)
KR (1) KR20220148237A (https=)
CN (1) CN115210263A (https=)
AR (1) AR121441A1 (https=)
AU (1) AU2021225490B2 (https=)
BR (1) BR112022015977A2 (https=)
CA (1) CA3170975A1 (https=)
CL (1) CL2022002259A1 (https=)
CO (1) CO2022012159A2 (https=)
IL (1) IL295596A (https=)
MX (1) MX2022010670A (https=)
MY (1) MY209381A (https=)
PE (1) PE20221783A1 (https=)
PH (1) PH12022552041A1 (https=)
WO (1) WO2021171257A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026001894A1 (zh) * 2024-06-24 2026-01-02 上海医药集团生物治疗技术有限公司 靶向axl的嵌合抗原受体及其用途
CN119591720B (zh) * 2024-11-28 2026-02-10 北京大学深圳研究生院 抗人axl抗体、基因及其应用
CN119912586B (zh) * 2024-12-31 2025-09-30 四川省肿瘤医院 基于受体酪氨酸激酶家族axl改造的嵌合抗原受体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
CA2706549A1 (en) * 2007-11-15 2009-05-22 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
BRPI1013428A2 (pt) * 2009-05-11 2019-07-02 U3 Pharma Gmbh anticorpos humanizados para axl
BR112012027995A2 (pt) * 2010-06-18 2017-01-10 Genentech Inc anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl
MX2015005757A (es) * 2012-11-08 2015-11-18 Hoffmann La Roche Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
JP6931609B2 (ja) 2014-12-18 2021-09-08 ベルゲン テクノロジオーヴァーフォリング エイエス 抗Axlアンタゴニスト抗体
CN108368171A (zh) * 2015-07-10 2018-08-03 根马布股份公司 用于癌症治疗的axl特异性抗体-药物缀合物
PL3368572T3 (pl) * 2015-10-02 2022-09-12 Symphogen A/S Przeciwciała anty-PD-1 oraz kompozycje
TN2018000333A1 (en) * 2016-04-12 2020-01-16 Symphogen As Anti-tim-3 antibodies and compositions
GB201610902D0 (en) * 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
CA3095986A1 (en) 2018-04-10 2019-10-17 Genmab A/S Axl-specific antibodies for cancer treatment

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
JP2023515821A5 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)
BR102021016176A2 (https=)